Fenostad 200

Fenofibrate, a fibric acid derivative, is a hypolipidemic drug. By inhibiting the hepatic biosynthesis of cholesterol, fenofibrate reduces atherogenic fractions and raises the production of HDL and reduces blood triglycerides. Thus, The repartition of plasma cholesterol is markedly ameliorated.

Pack size Box of 30 capsules
Shelf-life 36 months
Composition Fenofibrate
Dosage forms and strengths Hard gelatin capsule: 200 mg
Product code :



Fenostad 200 is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the following:

  • Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.
  • Mixed hyperlipidaemia when a statin is contraindicated or not tolerated or in patients at high cardiovascular risk in addition to a statin when triglycerides and HDL cholesterol are not adequately controlled.


  • Adults, geriatric populations: 1 tablet/day.
  • Renal impairment: Dosage reduction is required.
  • Severe chronic kidney disease, hepatic impairment, children < 18 years: Fenofibrate is not recommended for use.


  • Fenostad 200 should be swallowed whole during a meal.
  • Known hypersensitivity to any of the ingredients.
  • Severe renal dysfunction.
  • Hepatic insufficiency (including biliary cirrhosis and unexplained persistent liver function abnormality).
  • Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridemia.
  • Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen.
  • Known gallbladder disease.


  • Gastrointestinal disorders, epigastric fullness, nausea, meteorism, mild diarrhea;
  • Hives, urticaria, cutaneous non-specific rash;
  • Rise in serum transaminases;
  • Muscular pain.
  • In patients taking anticoagulants, the dose of anticoagulant should be reduced by about one third when treatment with fenofibrate is started. Check the prothrombin level more frequently and adapt the dosage of oral anticoagulant during treatment by fenofibrate and 8 days after its interruption.
  • Hypothyroidism may be a factor predisposing to the muscle syndrome.
  • Measurement of transaminases every 3 months, during the first 12 months of treatment, temporary interruption of treatment in case of an increase in SGPT (ALT) to > 100 IU.
  • Biliary complications are more prone to occur in patients with biliary cirrhosis or gallstones.
  • Fenofibrate therapy should be discontinued if serum CPK concentrations become markedly elevated or if myositis/myopathy is suspected or diagnosed.
  • Stevens-Johnson syndrome and toxic epidermal necrolysis, pancreatitis.
  • Pregnancy and lactation.
  • Patients should be aware of how they react to drug before driving or operating machinery.